PLoS Biology (Nov 2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

  • Antonio Muruato,
  • Michelle N. Vu,
  • Bryan A. Johnson,
  • Meredith E. Davis-Gardner,
  • Abigail Vanderheiden,
  • Kumari Lokugamage,
  • Craig Schindewolf,
  • Patricia A. Crocquet-Valdes,
  • Rose M. Langsjoen,
  • Jessica A. Plante,
  • Kenneth S. Plante,
  • Scott C. Weaver,
  • Kari Debbink,
  • Andrew L. Routh,
  • David Walker,
  • Mehul S. Suthar,
  • Pei-Yong Shi,
  • Xuping Xie,
  • Vineet D. Menachery

Journal volume & issue
Vol. 19, no. 11

Abstract

Read online

The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a pandemic causing significant damage to public health and the economy. Efforts to understand the mechanisms of Coronavirus Disease 2019 (COVID-19) have been hampered by the lack of robust mouse models. To overcome this barrier, we used a reverse genetic system to generate a mouse-adapted strain of SARS-CoV-2. Incorporating key mutations found in SARS-CoV-2 variants, this model recapitulates critical elements of human infection including viral replication in the lung, immune cell infiltration, and significant in vivo disease. Importantly, mouse adaptation of SARS-CoV-2 does not impair replication in human airway cells and maintains antigenicity similar to human SARS-CoV-2 strains. Coupled with the incorporation of mutations found in variants of concern, CMA3p20 offers several advantages over other mouse-adapted SARS-CoV-2 strains. Using this model, we demonstrate that SARS-CoV-2–infected mice are protected from lethal challenge with the original Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), suggesting immunity from heterologous Coronavirus (CoV) strains. Together, the results highlight the use of this mouse model for further study of SARS-CoV-2 infection and disease. Studying cross-protection from different coronaviruses is important to inform the research for a universal vaccine. This study uses a mouse-adapted SARS-CoV-2 strain to show that it confers protection from SARS-CoV challenge, suggesting possible immunity from heterologous challenge following natural infection.